SG10202111032PA - 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof - Google Patents
21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereofInfo
- Publication number
- SG10202111032PA SG10202111032PA SG10202111032PA SG10202111032PA SG10202111032PA SG 10202111032P A SG10202111032P A SG 10202111032PA SG 10202111032P A SG10202111032P A SG 10202111032PA SG 10202111032P A SG10202111032P A SG 10202111032PA SG 10202111032P A SG10202111032P A SG 10202111032PA
- Authority
- SG
- Singapore
- Prior art keywords
- hemophilia
- factor
- methods
- fusion proteins
- dosing regimen
- Prior art date
Links
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- 102000008100 Human Serum Albumin Human genes 0.000 title 1
- 108091006905 Human Serum Albumin Proteins 0.000 title 1
- 229960004222 factor ix Drugs 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762526377P | 2017-06-29 | 2017-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111032PA true SG10202111032PA (en) | 2021-11-29 |
Family
ID=62815032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111032PA SG10202111032PA (en) | 2017-06-29 | 2018-06-29 | 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof |
Country Status (15)
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2484966T3 (es) | 2000-04-12 | 2014-08-12 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| JP6250282B2 (ja) * | 2009-08-20 | 2017-12-20 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子 |
| KR20190104442A (ko) * | 2010-07-09 | 2019-09-09 | 바이오버라티브 테라퓨틱스 인크. | 인자 iｘ 폴리펩티드 및 이들의 사용 방법 |
| EP3542861A1 (en) * | 2012-09-25 | 2019-09-25 | Bioverativ Therapeutics Inc. | Methods of using fix polypeptides |
| SG11201604860RA (en) | 2013-12-23 | 2016-07-28 | Csl Ltd | Fusion proteins comprising factor ix for prophylactic treatment of hemophilia and methods thereof |
| MX2016013281A (es) * | 2014-04-11 | 2017-01-18 | Csl Ltd | Proteina del factor fviia con vida media extendida para la prevencion y tratamiento de sangrado y regimenes de dosificacion de la misma. |
-
2018
- 2018-06-29 SG SG10202111032PA patent/SG10202111032PA/en unknown
- 2018-06-29 ES ES18736860T patent/ES2963665T3/es active Active
- 2018-06-29 MX MX2019014651A patent/MX2019014651A/es unknown
- 2018-06-29 US US16/626,153 patent/US20200115436A1/en not_active Abandoned
- 2018-06-29 IL IL271160A patent/IL271160B2/en unknown
- 2018-06-29 EP EP18736860.0A patent/EP3645034B1/en active Active
- 2018-06-29 PL PL18736860.0T patent/PL3645034T3/pl unknown
- 2018-06-29 DK DK18736860.0T patent/DK3645034T5/da active
- 2018-06-29 AU AU2018294517A patent/AU2018294517B2/en active Active
- 2018-06-29 KR KR1020207002673A patent/KR102597725B1/ko active Active
- 2018-06-29 WO PCT/EP2018/067523 patent/WO2019002532A1/en unknown
- 2018-06-29 JP JP2019572377A patent/JP2020525498A/ja active Pending
- 2018-06-29 CN CN201880042643.9A patent/CN110799209A/zh active Pending
- 2018-06-29 RU RU2020103424A patent/RU2020103424A/ru unknown
- 2018-06-29 CA CA3068360A patent/CA3068360A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200019749A (ko) | 2020-02-24 |
| RU2020103424A3 (enrdf_load_stackoverflow) | 2021-11-12 |
| JP2020525498A (ja) | 2020-08-27 |
| DK3645034T3 (da) | 2023-11-20 |
| AU2018294517B2 (en) | 2024-09-26 |
| EP3645034B1 (en) | 2023-08-30 |
| KR102597725B1 (ko) | 2023-11-06 |
| IL271160A (en) | 2020-01-30 |
| RU2020103424A (ru) | 2021-07-29 |
| US20200115436A1 (en) | 2020-04-16 |
| CN110799209A (zh) | 2020-02-14 |
| IL271160B2 (en) | 2025-05-01 |
| WO2019002532A1 (en) | 2019-01-03 |
| PL3645034T3 (pl) | 2024-09-02 |
| IL271160B1 (en) | 2025-01-01 |
| ES2963665T3 (es) | 2024-04-01 |
| MX2019014651A (es) | 2020-02-07 |
| CA3068360A1 (en) | 2019-01-03 |
| EP3645034A1 (en) | 2020-05-06 |
| DK3645034T5 (da) | 2024-08-26 |
| AU2018294517A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257231A (en) | Factor ix fusion proteins and methods for their preparation and use | |
| IL273918A (en) | Trispecific proteins and methods of use | |
| ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| SG10201912680RA (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
| IL280102A (en) | Fusion protein containing PD1-4-1BBL and methods of using it | |
| EP3464608A4 (en) | THERAPEUTIC RECOMBINANT KLOTHO PROTEINS, COMPOSITIONS AND METHODS THEREFOR | |
| PL3310805T3 (pl) | Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie | |
| EP3490538A4 (en) | PARTICLES FOR THE DELIVERY OF PROTEINS AND PEPTIDES | |
| IL256515A (en) | Therapeutic peptides and methods of use thereof | |
| IL280103A (en) | Fusion protein containing SIRPalpha-4-1BBL and methods of using it | |
| EP3518971A4 (en) | Antibody and protein therapeutic formulations and uses thereof | |
| CL2018001724A1 (es) | Terapia combinada de inhibidores de proteinas extra-terminales y bromodominio | |
| EP3294286A4 (en) | Docetaxel and human serum albumin complexes | |
| IL245997A0 (en) | Fusion proteins containing factor ix for prophylactic treatment of hemophilia and methods of treatment | |
| SI3532059T1 (sl) | Kombinacijska terapija z bromodomeno in ekstra terminalnim inhibitorskim proteinom | |
| IL261740A (en) | Compositions and methods for treatment of type vii collagen deficiencies | |
| PT3387019T (pt) | Proteínas de fusão de imunoglobulina de relaxina e métodos de uso | |
| EP3305800C0 (en) | METHOD FOR PREPARING PLASMA-DERIVED HUMAN IMMUNOGLOBULIN AGENT AGAINST HEPATITIS B | |
| IL258238B (en) | Hiv antibody compositions and methods of use | |
| SG10202111032PA (en) | 21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof | |
| HUP1700057A2 (en) | Capsule configuration for slides and adventure field in amusement complex system | |
| EP3474826A4 (en) | PHARMACEUTICAL PREPARATION FOR THE ADMINISTRATION OF PEPTIDES AND PROTEINS | |
| PL3262069T3 (pl) | Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu | |
| PT3526244T (pt) | Péptidos derivados do propéptido ntsr3 e a sua utilização no tratamento da depressão | |
| PL3295916T3 (pl) | Pojemnik na preparat osocza ludzkiego i sposób jego otrzymywania |